Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
A 59-YEAR-OLD man with a 10-year history of diabetes had 2 months of decreasing visual acuity in both eyes. Ten months prior to being seen, the patient began treatment with gemcitabine hydrochloride for non-small-cell lung cancer and within 1 month developed a progressive ischemic peripheral vaso-occlusive disease involving the right fourth digit (Figure 1), the left first digit, left second digit, and the dorsal penis. Findings from an upper extremity arteriogram confirmed sluggish palmar arterial flow bilaterally, and laboratory studies revealed a Westergren erythrocyte sedimentation rate (ESR) of 117 and an antinuclear antibody ratio (ANA) of 1:1280. Gemcitabine administration was discontinued and oral prednisone administration was begun. The peripheral necrotic lesions were stabilized, and within 1 month the ESR was 38. However, the cutaneous lesions persisted with periodic exacerbations during the next 8 months, necessitating varying doses of corticosteroids for control.
Banach MJ, Williams GA. Purtscher Retinopathy and Necrotizing Vasculitis With Gemcitabine Therapy. Arch Ophthalmol. 2000;118(5):726–727. doi:10.1001/archopht.118.5.726
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: